These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 25492366)

  • 21. Novel iron-containing phosphate binders for treatment of hyperphosphatemia.
    Schmid H; Lederer SR
    Expert Opin Pharmacother; 2015; 16(14):2179-91. PubMed ID: 26293683
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of SBR759, a novel calcium-free, iron (III)-based phosphate binder, versus placebo in chronic kidney disease stage V Japanese patients on maintenance renal replacement therapy.
    Fukagawa M; Kasuga H; Joseph D; Sawata H; Junge G; Moore A; Akiba T
    Clin Exp Nephrol; 2014 Feb; 18(1):135-43. PubMed ID: 23670305
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ferric citrate controls serum phosphorus in dialysis patients: retrospective data
.
    Hain DJ; Marinaro M; Koeper DW; Rosenthal MA; Chillemi S; Huffman JM; Gerbeling T; Pritsiolas JM; Loram LC; Pergola PE
    Clin Nephrol; 2017 Jul; 88(1):12-18. PubMed ID: 28561732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study.
    Koiwa F; Terao A
    Clin Exp Nephrol; 2017 Jun; 21(3):513-522. PubMed ID: 27389681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rationale and study design of a three-period, 58-week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis.
    Umanath K; Sika M; Niecestro R; Connelly C; Schulman G; Koury MJ; Lewis JB; Dwyer JP;
    Hemodial Int; 2013 Jan; 17(1):67-74. PubMed ID: 22702490
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis.
    Yokoyama K; Akiba T; Fukagawa M; Nakayama M; Sawada K; Kumagai Y; Chertow GM; Hirakata H
    Nephrol Dial Transplant; 2014 May; 29(5):1053-60. PubMed ID: 24376274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
    Patel L; Bernard LM; Elder GJ
    Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current and potential treatment options for hyperphosphatemia.
    Carfagna F; Del Vecchio L; Pontoriero G; Locatelli F
    Expert Opin Drug Saf; 2018 Jun; 17(6):597-607. PubMed ID: 29783873
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ferric citrate (Auryxia) for hyperphosphatemia.
    Med Lett Drugs Ther; 2015 Dec; 57(1483):166-7. PubMed ID: 26633686
    [No Abstract]   [Full Text] [Related]  

  • 30. [Iron, aluminum, and lanthanum-based drugs for treatment of hyperphosphatemia].
    Matsumura K
    Yakugaku Zasshi; 2015; 135(4):545-9. PubMed ID: 25832833
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adherence rates to ferric citrate as compared to active control in patients with end stage kidney disease on dialysis.
    Jalal D; McFadden M; Dwyer JP; Umanath K; Aguilar E; Yagil Y; Greco B; Sika M; Lewis JB; Greene T; Goral S
    Hemodial Int; 2017 Apr; 21(2):243-249. PubMed ID: 27615161
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Pharmacological, pharmaceutical and clinical profiles of sucroferric oxyhydroxide (P-TOL
    Tatemichi S; Nakagaki F; Yoshioka S; Shichiri N
    Nihon Yakurigaku Zasshi; 2018; 151(2):75-86. PubMed ID: 29415929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Next-generation phosphate binders: focus on iron-based binders.
    Nastou D; Fernández-Fernández B; Elewa U; González-Espinoza L; González-Parra E; Sanchez-Niño MD; Ortiz A
    Drugs; 2014 Jun; 74(8):863-77. PubMed ID: 24848754
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Phosphate binders in chronic kidney disease: the positions of sevelamer].
    Fomin VV; Shilov EM; Svistunov AA; Milovanov IuS
    Ter Arkh; 2013; 85(6):96-9. PubMed ID: 23875200
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Iron-based Phosphate Binders for ESRD Patients].
    Cozzolino M; Mangano M; Magagnoli L; Di Lullo L; Galassi A; Brancaccio D; Bellasi A
    G Ital Nefrol; 2016; 33(4):. PubMed ID: 27545638
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Can ferric citrate lead to iron overload in peritoneal dialysis patients?
.
    Aslam N; Govani M; Basdeo LM; Wadei HM
    Clin Nephrol; 2020 May; 93(5):262-266. PubMed ID: 31933474
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of lanthanum carbonate in pre-dialysis CKD patients with hyperphosphatemia: a randomized trial.
    Takahara Y; Matsuda Y; Takahashi S; Shigematsu T;
    Clin Nephrol; 2014 Sep; 82(3):181-90. PubMed ID: 25079863
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric Oxyhydroxide.
    Cozzolino M; Funk F; Rakov V; Phan O; Teitelbaum I
    Curr Drug Metab; 2014; 15(10):953-65. PubMed ID: 25658128
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of phosphate binders in chronic kidney disease.
    Ketteler M; Biggar PH
    Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):413-20. PubMed ID: 23736841
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The safety and tolerability of ferric citrate as a phosphate binder in dialysis patients.
    Sinsakul M; Sika M; Koury M; Shapiro W; Greene T; Dwyer J; Smith M; Korbet S; Lewis J;
    Nephron Clin Pract; 2012; 121(1-2):c25-9. PubMed ID: 23075669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.